|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
FibroGen, Inc. and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease
12/12/2012 9:26:14 AM
SAN FRANCISCO & TOKYO--(BUSINESS WIRE)--FibroGen, Inc. (“FibroGen”), and Astellas Pharma Inc. (Tokyo:4503, “Astellas”), announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease (“CKD”) in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe. FG-4592/ASP1517 is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (a “HIF-PHI”), belonging to a new class of anemia therapeutic agents. The decision to initiate the Phase 3 program in the U.S. and Europe is based on the completion of Phase 2 clinical studies showing that FG-4592/ASP1517 met its primary objective of demonstrating anemia correction in treatment-naïve CKD patients not on dialysis as well as maintenance of hemoglobin in CKD patients on dialysis and not on dialysis. Results relating to Phase 2 clinical development of FG-4592/ASP1517 were most recently presented at the American Society of Nephrology Kidney Week 2012, in San Diego, California.
|
|
|
|
|
|
|
|
|
|
|